Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
   Or select

Or become a subscriber

Click here to view
our current issue


Potent Promise

Recent approvals have established the viability of antibody-drug conjugates, and open the door to future products that are more efficacious, better tolerated and applicable to broader patient populations.

Donald Bergstrom, Timothy Lowinger and Peter Park, Mersana Therapeutics (June 2014)

Keywords: Antibody-drug conjugates, DNA damaging agents, Tubulin binder, Drug-to-antibody ratio, Potent drug payloads

    View full article    |    Back to Biopharma section

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |